glasdegib maleate · Pfizer · NDA 210656
Daurismo
Earliest generic entry, as listed · earliest of 2 marketed strengths
13 Apr 2036
Blocked by patent: US 10414748, US 11168066, US 11891372.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10414748 | substance, product | 13 Apr 2036 |
| US 11168066 | use U-3254 | 13 Apr 2036 |
| US 11891372 | use U-3254 | 13 Apr 2036 |
| US 8148401 | substance, product | 21 Nov 2032 |
| US 8431597 | product | 29 Jun 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210656 · 001 · RLD | tablet, oral | EQ 25MG BASE | 13 Apr 2036 |
| 210656 · 002 · RLD | tablet, oral | EQ 100MG BASE | 13 Apr 2036 |